−106
Kalaris Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
−142
FY23:
−124
FY24:
−20.7
FY25:
−38.4
Change from FY21 to FY25
millions USD
FY21:
186
FY22:
−80.5
FY23:
38.0
FY24:
95.0
FY25:
−19.7
Change from FY21 to FY25
millions USD
FY21:
0.23
FY22:
127
FY23:
70.5
FY24:
19.1
FY25:
155
millions USD
FY21:
79.9
FY22:
−95.6
FY23:
−16.0
FY24:
−1.53
FY25:
96.9
(positive)
Change from FY21 to FY25
millions USD
FY21:
−106
FY22:
–
FY23:
–
FY24:
–
FY25:
−38.6
All amounts in millions USD